content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Kite Pharma, Inc. (KITE)

178.67
0.44
(0.25%)
Sep 11, 4:00PM EDT
content_middle

Kite Pharma (KITE), a new addition to RMi’s list of companies, is a clinical-stage biopharmaceutical company focused on development and commercialization of cancer immunotherapy products designed to harness a patient’s own immune system to eradicate cancer cells.  It is developing  a pipeline of product candidates for the treatment of advanced solid and hematological malignancies using its therapeutic platform – engineered Autologous Cell Therapy (eACT™) – in which a patient’s own T cells, or white blood cells, are engineered to recognize and destroy their cancer.  The patient’s immune system, particularly T cells, plays a critical role in identifying and killing cancer cells. KITE’s eACT™ technology involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs), or T cell receptors (TCRs).  Its technology has been developed in part through collaboration with the National Cancer Institute, Surgery Branch through a cooperative research and development agreement (CRADA).

Previous Close: 
178.23
Open: 
178.40
Bid: 
178.30
Ask: 
178.93
1yr Target Price: 
146.22
Day's Range: 
178.26 - 178.75
52wk Range: 
39.82 - 179.69
Volume: 
3961939
Average Daily Volume: 
1868360
Market Capitalization: 
10.22B
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
57181000M
content_right

Pages